Published on: August 1, 2007
A New Coated Stent Could Help Overcome In-Stent Thrombosis
        SurModics Inc. (NASDAQ: SRDX) and Paragon Medical recently announced a collaboration to develop an innovative stent system designed to treat coronary artery disease. This new system combines SurModics' FINALE Prohealing coating technology with Paragon's proprietary thin-walled coronary stent system, aiming to address the serious complication of in-stent thrombosis.
        According to interventional cardiologists, although rare, in-stent thrombosis can be a severe and potentially life-threatening issue for patients who have undergone stent implantation. The FINALE Prohealing coating from SurModics promotes the restoration of normal vascular structure and accelerates endothelial cell healing, not only helping to dissolve newly formed clots but also reducing restenosis. When combined with Paragon’s thin-walled stent system, this innovation could lead to a more effective coronary stent that delivers drug-eluting benefits while minimizing long-term concerns about in-stent thrombosis.
        Bruce Barclay, CEO of SurModics, expressed excitement about the partnership with Paragon and Apollo, noting that early preclinical results of the FINALE coating technology have given the company confidence in its potential.
        The FINALE coating incorporates extracellular matrix (ECM) proteins, which support the body's natural healing process after a medical device is implanted, thereby enhancing and accelerating tissue repair. Blood clots remain a significant challenge in coronary stent procedures, and researchers and manufacturers are actively seeking solutions. Delayed or incomplete regeneration of healthy endothelial cells after stent placement may contribute to new clot formation. Working with Dr. Williams, SurModics aims to speed up the natural healing process of blood vessels by incorporating ECM proteins into the coating. Dr. Williams, a leading expert in tissue engineering, has been developing advanced cardiovascular implants. This approach holds promise for restoring the normal endothelial lining of the vessel. SurModics, along with Dr. Williams and the University of Arizona, conducted preclinical studies on the FINALE-coated stents, and the results were very encouraging.
        Apollo’s coronary stents utilize Paragon’s advanced technology, resulting in thinner walls and smaller diameters, making them easier to deliver via catheter. This innovation addresses a common issue in stent manufacturing—stent recoil when mounted onto the balloon. By using advanced metal alloys, such as cobalt-based materials, the new technology allows the stent to remain closed during delivery, ensuring better performance and usability. ——Shanghai Medical Device Industry Association
Fish,Frozen Fish,Frozen Fish Fillets,Fresh Hairtail Section
Zhoushan Haiwang Seafood Co., Ltd. , https://www.haiwangseafoods.com